MDM2 expression in the progression of Barrett’s oesophagus
Robinson, Leora; Ilyas, Mohammad; Ragunath, Krish; Card, Timothy R.; Abradu-Berchie, Berice; Kaye, Philip
MOHAMMAD ILYAS firstname.lastname@example.org
Professor of Pathology
Dr TIM CARD email@example.com
Clinical Associate Professor
Barrett's oesophagus (BO) is the main precursor for oesophageal adenocarcinoma (OAC), and dysplasia arising within it is the standard marker used to predict risk of malignant progression. However, dysplasia diagnosis is subject to a significant amount of interobserver variation. Biomarkers may aid the diagnosis of dysplasia and may help predict the risk of progression to OAC. Abnormal expression of p53 can be reproducibly detected by immunohistochemistry (IHC) and it is an effective marker of risk of OAC1. There is however still a need for additional early stage markers.
Robinson, L., Ilyas, M., Ragunath, K., Card, T. R., Abradu-Berchie, B., & Kaye, P. (2018). MDM2 expression in the progression of Barrett’s oesophagus. Histopathology, 72(7), 1230-1233. https://doi.org/10.1111/his.13480
|Journal Article Type||Article|
|Acceptance Date||Feb 2, 2018|
|Online Publication Date||Feb 10, 2018|
|Publication Date||Jun 30, 2018|
|Deposit Date||Feb 7, 2018|
|Publicly Available Date||Feb 11, 2019|
|Peer Reviewed||Peer Reviewed|
|Keywords||Barret’s oesophagus; MDM2; p53; Dysplasia|
|Additional Information||This is the peer reviewed version of the following article: Robinson, L., Ilyas, M., Ragunath, K., Card, T., Abradu-Berchie, B. and Kaye, P. (), MDM2 Expression in the Progression of Barrett's Oesophagus. Histopathology. Accepted Author Manuscript. doi:10.1111/his.13480
, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/his.13480/abstract. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Updated - MDM2 Expression in the Progression of Barrett final PVK histopathology update jan 2018 leora edit.pdf
You might also like
Saliva for COVID-19 testing: Simple but useless or an undervalued resource?